EN DE

IVF_INSPIRE IVF (IVF) Fair Value & Analysis

Healthcare · TH · Market cap 334M THB

II IVF_INSPIRE IVF IVF · BK
Price0.7700 THB
Fair Value0.9100 THB
Upside+18.2%
Quality33/100
Watch IVF_INSPIRE IVF for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -32.8% net margin
negative free cash flow
Trails peers (3/9)
Narrow moat 11/100
Evidence: Low Range 0.6000 THB – 1.14 THB Share as image

Fair value as of: Aug 13, 2026

From 1 valuation models · updated 4 days ago

Share price +1.3% over the past month.

Below-average quality, screening 18% undervalued on our models.

What matters now

  • A fairly wide model range (0.6000 THB to 1.14 THB) leaves room in how you read the outcome.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (20 months)

1.98 THB 0.5400 THB Fair Value 0.9100 THB Dec 2024 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

20‑month range 0.5400 THB – 1.98 THB · fair‑value band 0.6000 THB – 1.14 THB · the 0.7700 THB price screens below the 0.9100 THB fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

IVF_INSPIRE IVF (IVF) currently trades at 0.7700 THB, while our model-based Fair Value estimate is 0.9100 THB, implying the stock looks roughly 18.2% undervalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, IVF_INSPIRE IVF generated revenue of 65.9M THB at a net margin of -32.8%. Revenue declined 20.9% year over year. It earns a return on equity of -4.0%. Net debt stands at 11.5M THB. Fundamentals as of Aug 13, 2026

Our scenario range runs from 0.6000 THB (bear case) to 1.14 THB (bull case); at 0.7700 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 54% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 18%, IVF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) 0.6000 THB 0.8000 THB 1.20 THB 50
All 1 models by family
Asset-Based
NCAV (Graham) 0.6000 THB 0.8000 THB 1.20 THB 50

Notify me when IVF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 65.9M THB
Revenue growth (YoY) -20.9%
Net margin -32.8%
Return on equity -4.0%
Free cash flow −13.9M THB FY2025
Operating margin -61.4%
More key figures
EPS (TTM) -0.0500 THB
Net debt 11.5M THB FY2021

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 33/100

Of which business quality 38 · Market factors (momentum, volatility) 33

Profitability 4
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 37
Price trend over the last 3–12 months (market factor)
52W Momentum 22
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Inspire IVF Public Company Limited operates an infertility treatment center in Thailand. It offers intrauterine insemination, preimplantation genetic testing, intracytoplasmic sperm injection, embryo transfer, fertility preservation, preventive and regenerative medicine, health checkup, and other infertility treatments.

Full company description

Inspire IVF Public Company Limited operates an infertility treatment center in Thailand. It offers intrauterine insemination, preimplantation genetic testing, intracytoplasmic sperm injection, embryo transfer, fertility preservation, preventive and regenerative medicine, health checkup, and other infertility treatments. The company provides obstetrics and gynecology examinations, consulting, and advice, as well as age management medicine, health regeneration, blood dialysis, and blood filtration services. Inspire IVF Public Company Limited was incorporated in 2018 and is based in Bangkok, Thailand.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IVF_INSPIRE IVF reported revenue of 61.9M THB in FY2025 versus 11.2M THB in FY2021, a compound +53.2%/yr. Reported net income was −17.4M THB in FY2025.

Growth Quality 3/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
61.9M THB
Latest YoY
−41.5%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.8%
Revenue +53.2%/yr
FY21 11.2M THB
FY22 63.3M THB
FY23 122M THB
FY24 106M THB
FY25 61.9M THB
Net income
FY21 −5.1M THB
FY22 10.1M THB
FY23 41.0M THB
FY24 22.2M THB
FY25 −17.4M THB

Watch IVF: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "IVF_INSPIRE IVF Fair Value". https://www.fairvalue-calculator.com/stock/IVF.BK

Peer Group

Medical Care Facilities · 267 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 38 · Bottom 25%
Fair Value upside +18% · Above median
Return on assets -2% · Bottom 25%
Net margin (TTM) -33% · Bottom 25%
Operating margin (TTM) -61% · Bottom 25%
Revenue growth -21% · Bottom 25%
Dividend yield (TTM) 3.9% · Top 25%

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/S (TTM) 0.15× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 58 · sector 27
FUTURE 0 · sector 23
PAST 0 · sector 29
HEALTH 0 · sector 90
DIVIDEND 77 · sector 41

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Compare IVF_INSPIRE IVF with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is IVF_INSPIRE IVF (IVF) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 0.9100 THB versus a price of 0.7700 THB, about +18% (undervalued).
What is the fair value of IVF?
Our model-based fair value for IVF_INSPIRE IVF is 0.9100 THB (as of Aug 13, 2026), built from audited fundamentals. The current price is 0.7700 THB.
What is the quality score of IVF?
IVF_INSPIRE IVF has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of IVF_INSPIRE IVF (IVF)?
IVF_INSPIRE IVF reported trailing-twelve-month revenue of about 65.9M THB (latest available figure, as of Aug 13, 2026).
What is the net profit margin of IVF?
The net profit margin of IVF_INSPIRE IVF is about -32.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track IVF_INSPIRE IVF and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.